Search for: [Abstract = "ponse to the treatment revealed adverse impact of the type of applicator \(Ru\-106\), tumour location \(the front edge – rearwardly from the equator of the eye, the rear edge \- in close proximity to the optic nerve\), the apical height radiation dose \( 100 Gy\) and the base diameter of the tumour \( 10 mm\).During the entire time of the study tumour metastases were found in 25 patients \(14.6%\) treated with Ru\-106 therapy and in 31 patients \(15.1%\) treated with I\-125 therapy. The most common site of metastases was the liver \(89.3%\). Less frequent sites included the lungs, brain, skin, pancreas, adrenal glands, spinal cord, spleen and ureter. Cox proportional hazards model revealed the correlation between the type of tumour regression \(model I\), retinal detachment, the location of the rear edge of the tumour rearwardly from the equator of the eyeball, and the occurrence of metastases.During the whole period of observation the enucleation procedure was performed in 47 patients \(12.5%\), including 24 \(14%\) treated with Ru\-106 isotope and 23 \(11.2%\) treated with I\-125 isotope. In 95.8% of the patients treated with Ru\-106 brachytherapy the indication for removal of the eyeball was a relapse and the primary lack of treatment response, whereas in the group treated with I\-125 isotope the main indication for surgery constituted postradiation complications \(78.3%\). Cox analysis demonstrated a si"]

Number of results: 1